CHMP meeting highlights – May 2025
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
List view / Grid view
The EMA’s committee has granted positive opinions for ten new treatments, including medicines for oncology indications and rare diseases.
Outsourcing the production of oral solids is estimated to be the primary influencer for the contract manufacturing market in the next decade, using lessons learnt from the COVID-19 pandemic.
Trial finds neither azithromycin nor doxycycline meaningfully improve recovery times or reduce risk of hospitalisation in non-hospitalised COVID-19 patients.
A double-blind clinical trial has begun in the US to study hydroxychloroquine and azithromycin treatment in patients with COVID-19.
The COVID-19 European Medicines Agency (EMA) pandemic Task Force (COVID-ETF) warned that chloroquine and hydroxychloroquine are yet to be proved effective at treating COVID-19 and that their side effects could be fatal.
The PRINCIPLE trial aims to evaluate therapeutics that could slow the progression of COVID-19 symptoms in patients most at risk of complications.
Zoliflodacin was found to be effective in curing all rectal gonorrheal infections in patients during a Phase II clinical trial...
Scientists show how the gonorrhoea bacterium resists last-resort antibiotic ceftriaxone while maintaining a robust growth rate...
Treating people who start HIV treatment late with a package of low-cost drugs to prevent serious infections saves three lives for ...